Literatur
- 1
Pauwels R A, Buist A S, Ma P. et al .
GOLD Scientific Committee. Global Strategy for the Diagnosis, Management, and Prevention
of Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med.
2001;
163
1256-1276
- 2 National Heart & Lung Institute, World Health Organization .Global Strategy for
the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
Executive Summary. NIH Publication No. 2701A. March 2001
- 3
Antonelli-Incalzi R, Imperiale C, Bellia V. et al .
SaRA Investigators. Do GOLD stages of COPD severity really correspond to differences
in health status?.
Eur Respir J.
2003;
22
444-449
- 4
Kornmann O, Beeh K M, Beier J. et al .
Global Initiative for Obstructive Lung Disease. Newly diagnosed chronic obstructive
pulmonary disease. Clinical features and distribution of the novel stages of the Global
Initiative for Obstructive Lung Disease.
Respiration.
2003;
70
67-75
- 5
Vestbo J, Lange P.
Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary
disease?.
Am J Respir Crit Care Med.
2002;
166
329-332
- 6
Iqbal A, Schloss S, George D. et al .
Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis
and treatment recommendations.
Respirology.
2002;
7
233-239
- 7 National Heart & Lung Institute, World Health Organization .Global Strategy for
the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
Executive Summary. Updated 2003. NIH Publication No. 2701A. Juli 2003
- 8
ZuWallack R L, Mahler D A, Reilly D. et al .
Salmeterol plus theophylline combination therapy in the treatment of COPD.
Chest.
2001;
119
1661-1670
- 9
Mahler D A, Donohue J F, Barbee R A. et al .
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest.
1999;
115
957-965
- 10
Dahl R, Greefhorst L A, Nowak D. et al .
Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol
dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
164
778-784
- 11
Bellia V, Foresi A, Bianco S. et al .
BREATH Italian Study Group. Efficacy and safety of oxitropium bromide, theophylline
and their combination in COPD patients: a double-blind, randomized, multicentre study
(BREATH Trial).
Respir Med.
2002;
96
881-889
- 12
Vincken W, Noord J A van, Greefhorst A P. et al .
Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD
during 1 yr's treatment with tiotropium.
Eur Respir J.
2002;
19
209-216
- 13
Mahler D A, Wire P, Horstman D. et al .
Effectiveness of fluticasone propionate and salmeterol combination delivered via the
Diskus device in the treatment of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2002;
15 (166)
1084-1091
- 14
Kroegel C, Reißig A, Bonnet R. et al .
Aktuelle Entwicklungen in der Pneumologie - Update Pneumologie 2002 - Teil 1.
Med Klinik.
2003;
98
30-56
- 15
Noord J A van, Bantje T A, Eland M E. et al .
A randomised controlled comparison of tiotropium and ipratropium in the treatment
of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.
Thorax.
2000;
55
289-294
- 16
Casaburi R, Mahler D A, Jones P W. et al .
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary
disease.
Eur Respir J.
2002;
19
217-224
- 17
Burge P S, Calverley P M, Jones P W. et al .
Randomised, double blind, placebo controlled study of fluticasone propionate in patients
with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ.
2000;
320 (7245)
1297-1303
- 18
Vestbo J, Sorensen T, Lange P. et al .
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
1999;
353 (9167)
1819-1823
- 19
Pauwels R A, Lofdahl C G, Laitinen L A. et al .
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive
pulmonary disease who continue smoking. European Respiratory Society Study on Chronic
Obstructive Pulmonary Disease.
N Engl J Med.
1999;
340
1948-1953
- 20
Calverley P, Pauwels R, Vestbo J. et al .
Trial of inhaled steroids and long-acting β2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic
obstructive pulmonary disease: a randomised controlled trial.
Lancet.
2003;
361 (9356)
449-456
- 21
Jones P W, Willits L R, Burge P S. et al .
Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease
severity and the effect of fluticasone propionate on chronic obstructive pulmonary
disease exacerbations.
Eur Respir J.
2003;
21
68-73
- 22
Szafranski W, Cukier A, Ramirez A. et al .
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease.
Eur Respir J.
2003;
21
74-81
- 23
Behnke M, Taube C, Kirsten D. et al .
Home-based exercise is capable of preserving hospital-based improvements in severe
chronic obstructive pulmonary disease.
Respir Med.
2000;
94
1184-1191
- 24
Finnerty J P, Keeping I, Bullough I. et al .
The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease:
a randomized controlled trial.
Chest.
2001;
119
1705-1710
- 25
Green R H, Singh S J, Williams J. et al .
A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation
in chronic obstructive pulmonary disease.
Thorax.
2001 Feb;
56 (2)
143-145
- 26
Davies L, Wilkinson M, Bonner S. et al .
„Hospital at home” versus hospital care in patients with exacerbations of chronic
obstructive pulmonary disease: prospective randomised controlled trial.
BMJ.
2000;
321 (7271)
1265-1268
- 27
Hernandez C, Casas A, Escarrabill J. et al .
CHRONIC project. Home hospitalisation of exacerbated chronic obstructive pulmonary
disease patients.
Eur Respir J.
2003;
21
58-67
- 28
Ojoo J C, Moon T, McGlone S. et al .
Patients' and carers' preferences in two models of care for acute exacerbations of
COPD: results of a randomised controlled trial.
Thorax.
2002;
57
167-169
Claus Kroegel
Pneumologie & Allergologie · Medizinische Klinik I, Friedrich-Schiller-Universität
Erlanger Allee 101
07740 Jena
Email: claus.kroegel@med.uni-jena.de
